Jyong Biotech Ltd.

# Jyong Biotech Ltd. (MENS)

Founded in 2002 and based in New Taipei City, Taiwan, this biotechnology company develops plant-derived pharmaceutical compounds targeting urinary and reproductive system disorders. The firm operates across the United States, European Union, and Asia, pursuing a pipeline focused on conditions with limited treatment options. Its clinical programs include MCS-2 for benign prostate hyperplasia and lower urinary tract symptoms, a compound designated PCP for prostate cancer treatment, and a candidate for interstitial cystitis and bladder pain syndrome.

The company operates as a development-stage biotech entity with a plant-based drug discovery model. Its revenue streams are derived from the advancement of these proprietary compounds through clinical development phases, though the firm remains pre-commercial for most candidates. Geographic diversification across multiple regulated markets reflects the company's strategy to pursue approvals and commercialization opportunities in established healthcare systems.

With a market capitalization of $0.2 billion, Jyong Biotech represents a micro-cap biotechnology player. The company is incorporated in the Cayman Islands and listed on Nasdaq, providing access to U.S. capital markets. Specific employee count and current-stage revenue figures are not available in public filings reviewed.